A phase II study (KAMELEON) of single-agent T-DM1 in 69 patients with HER2-positive advanced urothelial bladder cancer showed an ORR of 38.5% (95% CI, 16.6 to 64.5) [27]. This evidence concerns the gene ERBB2 and bladder transitional cell carcinoma.